Sym-021
- Generic Name
- Sym-021
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 48
- Registration Number
- NCT04672434
- Locations
- ๐บ๐ธ
NEXT Oncology, San Antonio, Texas, United States
๐บ๐ธMD Anderson Cancer Center, Houston, Texas, United States
๐จ๐ฆPrincess Margaret Cancer Centre, Toronto, Ontario, Canada
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
Phase 1
Completed
- Conditions
- Metastatic CancerSolid Tumor
- Interventions
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 78
- Registration Number
- NCT04641871
- Locations
- ๐บ๐ธ
MD Anderson, Houston, Texas, United States
๐บ๐ธUniversity of Kansas Medical Center (KUMC), Westwood, Kansas, United States
๐บ๐ธSTART Midwest, Grand Rapids, Michigan, United States
Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Phase 1
Completed
- Conditions
- Solid TumorMetastatic CancerLymphoma
- Interventions
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 89
- Registration Number
- NCT03311412
- Locations
- ๐บ๐ธ
South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States
๐บ๐ธThe University of Texas MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธNEXT Oncology, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath